Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHF8 | Q9UPP1 | 7/20 | 0.64 |
| ▸ | KDM2B | Q8NHM5 | 7/20 | 0.64 |
| ▸ | KDM4C | Q9H3R0 | 13/20 | 0.62 |
| ▸ | KDM5A | P29375 | 4/20 | 0.62 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17604552 | 0.92 | PHF8 (0.63) | PHF8KDM2BKDM4CKDM5AKDM5B | |
| SCHEMBL17621559 | 0.86 | KDM4C (0.75) | PHF8KDM2BKDM4CKDM5AKDM5B | |
| SCHEMBL17604592 | 0.84 | KDM4C (0.72) | PHF8KDM2BKDM4CKDM5AKDM5B | |
| SCHEMBL17693137 | 0.83 | KDM4C (0.73) | PHF8KDM2BKDM4CKDM5AKDM5B | |
| SCHEMBL17686548 | 0.83 | KDM4C (0.72) | PHF8KDM2BKDM4CKDM5AKDM5B | |
| SCHEMBL17604666 | 0.82 | PHF8 (0.74) | PHF8KDM2BKDM4CKDM5AKDM5B | |
| SCHEMBL17621524 | 0.81 | KDM4C (0.70) | PHF8KDM2BKDM4CKDM5AKDM5B | |
| SCHEMBL18949672 | 0.81 | KDM4C (0.70) | PHF8KDM2BKDM4CKDM5AKDM5B | |
| SCHEMBL17604517 | 0.81 | KDM2B (0.65) | PHF8KDM2BKDM4CKDM5AKDM5B | |
| SCHEMBL17604536 | 0.80 | PHF8 (0.39) | PHF8KDM2BKDM4CKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3193881-A1 | HISTONE DEMETHYLASE INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044342-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |